Management of multiple myeloma patients with renal disease

Abstract

Multiple myeloma (MM) is a plasma cell dyscrasia, accounting for 10% of all hematological malignancies, which translates into a global age-standardized incidence and mortality rate of 2:1 per 100.000 and 1.39 per 100.000 respectively (1). Kidney disease is a very common complication of MM, increasing the mortality and being a poor prognostic factor. Renal impairment is often the first reason for patient admission, leading to the plasma cell dyscrasia as being the cause. 40% of patients with cast nephropathy had previously undiagnosed myeloma (2). The aim of this paper is to show that Prompt diagnosis and initiation of therapy warrents better patient survival and delays, or even prevents organ damage in multiple myelmoma.

Keywords

• multiple myeloma
• kudney disease
• chemotherapy
• immunomodulatory drugs
• kidney transplant